BRIEF-InnoCare Announces NMPA Approval Of Phase II Clinical Trial Of TYK2 Inhibitor ICP-488

InnoCare Announces Nmpa Approval of a Phase Ii Clinical Trial of Tyk2 Inhibitor Icp-488 for Cutaneous Lupus Erythematosus

HK Stock Movement | INNOCARE (09969) Rises Over 4% as Self-Developed Novel TYK2 Inhibitor ICP-332 Gains Approval for Phase II/III Clinical Trials in CSU Treatment

InnoCare Pharma Wins China Approval for Phase II/III Trial of TYK2 Inhibitor in Chronic Urticaria

InnoCare Announces Approval of Phase Ii/Iii Clinical Trial of Novel Tyk2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

Zenas BioPharma Reports Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Study

InnoCare Pharma Wins Approval to Start Phase III Trial of Orelabrutinib for SLE

InnoCare Announces Achievement of Primary Endpoint in Phase Iib Study of Orelabrutinib for Sle and Approval of Phase Iii Clinical Trial

Innocare Pharma Limited (688428.SH): Orelabrutinib Meets Primary Endpoint in Phase IIb Study for Systemic Lupus Erythematosus

HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon

BRIEF-Innocare Pharma Announces Approval Of Zurletrectinib By China's NMPA

InnoCare Pharma Gets China Nod for Tumor Drug

InnoCare Pharma Ltd - Approval of Zurletrectinib by China's Nmpa

InnoCare Pharma Showcases Over 20 Orelabrutinib Studies Highlighting Efficacy in Lymphoma at ASH 2025

InnoCare Pharma Reports High Remission Rates for Mesutoclax in Relapsed/Refractory Lymphoma and Leukemia Trials

InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

InnoCare Announces First Patient Dosed in the Global Phase Ii Clinical Trial of Tyk2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare Pharma Logs Over 34 Million Yuan in Q3 Loss

BRIEF-Innocare Pharma Logs 9M Gross Margin 88.8%

InnoCare Pharma Files Directors List with HKEX